ZURICH (Reuters) – Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States on Thursday.
“Our pipeline is industry-leading with more than 25 potential blockbusters and this pace of innovation positions Novartis well for the future”, said Novartis Chief Executive Vas Narasimhan in a statement.
(Reporting by Silke Koltrowitz)
